ovarian clear cell carcinoma (Cancer)
Information
- Disease name
- ovarian clear cell carcinoma
- Disease ID
- DOID:0050934
- Description
- "An ovarian carcinoma that has_material_basis_in cells with clear cytoplasm and glycogen secreting hob nail cells." [url:http\://en.wikipedia.org/wiki/Clear-cell_ovarian_carcinoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03297424 | Completed | Phase 1 | A Study of PLX2853 in Advanced Malignancies. | September 12, 2017 | June 7, 2021 |
| NCT01914510 | Completed | Phase 2 | A Study of ENMD-2076 in Ovarian Clear Cell Cancers | September 2013 | January 2017 |
| NCT06279104 | Not yet recruiting | A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary | March 1, 2024 | May 1, 2025 | |
| NCT05600998 | Not yet recruiting | N/A | A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma | October 30, 2022 | February 28, 2024 |
| NCT05759312 | Not yet recruiting | Phase 1/Phase 2 | Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma | March 2023 | February 2025 |
| NCT04104776 | Recruiting | Phase 1/Phase 2 | A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | September 18, 2019 | March 1, 2026 |
| NCT05296512 | Recruiting | Phase 2 | Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer | September 23, 2022 | May 15, 2027 |
| NCT05415098 | Recruiting | Phase 1 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | September 30, 2022 | September 30, 2025 |
| NCT05498597 | Recruiting | Phase 1 | AMT-151 in Patients With Selected Advanced Solid Tumours | January 25, 2023 | October 30, 2024 |
| NCT06065462 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 | November 10, 2023 | January 31, 2026 |
| NCT05099978 | Recruiting | Asian Multicenter Prospective Study of ctDNA Sequencing | November 1, 2021 | December 31, 2024 | |
| NCT05226507 | Recruiting | Phase 1 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer | December 31, 2021 | June 2025 |
| NCT05281471 | Recruiting | Phase 3 | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | August 31, 2022 | October 2026 |
| NCT02837991 | Terminated | Phase 1 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma | June 2016 | November 16, 2018 |
| NCT04735861 | Unknown status | Phase 2 | Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma | April 7, 2021 | April 30, 2024 |
| NCT03405454 | Unknown status | Phase 2 | A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas | October 9, 2017 | March 15, 2022 |
| NCT02866370 | Unknown status | Phase 2 | Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium | April 2015 | March 2021 |
- Disase is a (Disease Ontology)
- DOID:4001
- Exact Synonym (Disease Ontology)
- clear-cell ovarian carcinoma